Phase 3 data for bulevirtide for hepatitis D have been published in the New England Journal of Medicine.

Published Date: 08 Jul 2023

Bulevirtide, a first-in-class investigational hepatitis delta virus entry-inhibitor, significantly decreased viral load and normalized liver enzyme levels in patients.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Common intracellular toxin could help fight leukemia

2.

CAR T-Cell Therapy Shows Promise in Mantle Cell Lymphoma

3.

Scholastic performance is a key concern for young cancer patients, study finds

4.

AACR: American Association for Cancer Research

5.

Lung Cancer Screening Rates in Eligible Adults Remain Low, Uneven


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot